Elan’s Alzheimer immunotherapy program (AIP) has gotten a booster. The company announced today that Johnson & Johnson has agreed to acquire all the assets of the program for an injection of $1 billion—the equivalent of ~18 percent of outstanding Elan ordinary shares. Through a new affiliate, Johnson & Johnson will continue the AIP in collaboration with Wyeth, and will also contribute $500 million for the development of bapineuzumab, a humanized monoclonal antibody against amyloidβ, the peptide found in senile plaques (see ARF related news story). Elan will own 49.9 percent of the new company according to a press release issued today.

Bapineuzumab is currently in Phase 3 clinical trials (see ARF related news story), and Elan has other immunotherapies for Alzheimer disease in the pipeline, including another monoclonal antibody AAB-001 and an Aβ vaccine (see ARF related news story). For more information on the new merger, see today’s New York Times.—Tom Fagan.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Chicago: Bapineuzumab’s Phase 2—Was the Data Better Than the Spin?
  2. Research Brief: Elan/Wyeth Vaccine Back on Track

Other Citations

  1. ARF related news story

External Citations

  1. press release
  2. AAB-001
  3. New York Times

Further Reading

News

  1. Research Brief: Elan/Wyeth Vaccine Back on Track
  2. Chicago: Bapineuzumab’s Phase 2—Was the Data Better Than the Spin?
  3. Out-of-Control Inflammation in Parkinson's: It's Glia, Again